We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Paper-Based Microfluidics Developed for Molecular Diagnostic Testing

By LabMedica International staff writers
Posted on 01 Apr 2014
A low cost, safe, disposable, rapid and self-sustainable paper-based platform for diagnostic testing, known as lab-on-paper, has been developed. More...


Such diagnostic tests are in high demand, targeting diseases such as tuberculosis and leishmaniasis, mainly in the developing world, where they remain major impoverishment factors for local communities and there is a strong interest in the use of biopolymers in the electronic and biomedical industries, towards low-cost applications.

Scientists at the Universidade Nova de Lisboa (Lisbon, Portugal) have developed paper-based microfluidics for molecular diagnostic testing. Paper properties were evaluated and compared to nitrocellulose, the most commonly used material in lateral flow and other rapid tests. They focused on the use of paper as a substrate for microfluidic applications, through an eco-friendly wax-printing technology, with three main and distinct colorimetric approaches: enzymatic reactions, immunoassays, and nucleic acid sequence identification.

Colorimetric glucose quantification was achieved through enzymatic reactions performed within specific zones of the paper-based device. The coloration achieved increased with growing glucose concentration and was highly homogeneous, covering all the surface of the paper reaction zones in a three dimensional (3D) sensor format. These devices showed a major advantage when compared to the 2D lateral flow glucose sensors, where some carryover of the colored products usually occurs.

The detection of anti-Leishmania antibodies in canine sera was conceptually achieved using a paper-based 96-well enzyme-linked immunosorbent assay format. However, optimization is still needed for this test, regarding the efficiency of the immobilization of antigens on the cellulose fibers. The detection of Mycobacterium tuberculosis (MTB) nucleic acids integrated with a non-cross-linking gold nanoprobe detection scheme was also achieved in a wax-printed 384-well paper-based microplate, by the hybridization with a species-specific probe. The whole process, including the polymerase chain reaction (PCR) amplification step, takes less than two-and-half hours, which is considerably faster than traditional methods.

The authors concluded that they obtained results with the easy-to-use diagnostic biosensors that show promise towards the future development of simple and cost-effective paper-based diagnostic devices. In future studies, they will simplify the paper-platform assay for MTB by the elimination of the polymerase chain reaction step, which depends on the use of thermocycler equipment and its replacement by an undemanding isothermal DNA amplification such as loop-mediated isothermal DNA amplification (LAMP). The study was published on February 12, 2014, in the journal Nanotechnology.

Related Links:

Universidade Nova de Lisboa 



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.